bs-23379R-APC [Conjugated Primary Antibody]
Aβ1-42 (CT), APC Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Aβ1-42 (CT)

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 351

Swiss Prot: P05067

Source: KLH conjugated synthetic peptide derived from human Aβ1-42 (CT)

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.

Conjugation: APC

Excitation/ Emission: 650nm/660nm

Size: 100ul

Concentration: 1mg/ml

Applications: IF(IHC-P)(1:100-500)
IF(IHC-F)(1:100-500)
IF(ICC)(1:100-500)

Predicted Molecular Weight: 87


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Tiantian Ye. et al. Borneol regulates meningeal lymphatic valve plasticity to clear A aggregates in the prevention of AD-like symptoms. PHYTOMEDICINE. 2024 May;:155753Read more>>
  • Qifeng Shi. et al. PLC-CN-NFAT1 signaling-mediated A and IL-1 crosstalk synergistically promotes hippocampal neuronal damage. INT IMMUNOPHARMACOL. 2024 Jun;134:112259Read more>>